Clinical Trials
11 trialsNCT05300282 2026-01-28
FIL_A-BEGEV
Fondazione Italiana Linfomi - ETS
Phase 1/2 Recruiting
NCT03739619 2025-08-06
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Emory University
Phase 1/2 Completed
NCT02733042 2023-11-18
FUSION NHL 001
Celgene
Phase 1/2 Completed
NCT01535924 2021-11-19
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT02059239 2021-02-21
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
Weill Medical College of Cornell University
Phase 1/2 Completed
NCT01657331 2020-07-17
SGN+Benda
Columbia University
Phase 1/2 Completed
NCT03343652 2020-05-28
NB001
St. Petersburg State Pavlov Medical University
Phase 1/2 Completed
NCT01326702 2019-12-16
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01874054 2019-02-12
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Seagen Inc.
Phase 1/2 Completed
NCT01165112 2018-12-05
TREC
University of Washington
Phase 1/2 Completed
NCT01412307 2015-08-11
LEBEN
GiovanniPascale
Phase 1/2 Unknown